statements

Everest Organics Ltd.

BSE: 524790

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

299.95-9.0 (-2.93%)

21 Aug, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Everest Organics Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	61.05	79.64	96.04	105.98	99.48	106.89	112.17	155.85	167.21	181.57	200.05	183.05	197.24	159.48	196.16	190.78
Cost of Operating Revenue	42.61	58.39	69.05	72.91	65.24	69.99	72.36	115.37	120.62	131.64	164.73	153.82	154.85	104.51	129.84	125.19
Gross Profit	18.44	21.24	26.99	33.07	34.23	36.91	39.81	40.48	46.59	49.93	35.32	29.23	42.40	54.97	66.32	65.59
Gross Margin	30.2	26.7	28.1	31.2	34.4	34.5	35.5	26.0	27.9	27.5	17.7	16.0	21.5	34.5	33.8	34.4
Total Operating Expenses	57.29	76.31	93.03	100.87	96.22	103.33	107.77	140.84	150.91	162.03	197.30	186.15	192.05	158.22	182.83	177.63
Operating Profit	3.76	3.32	3.01	5.11	3.25	3.56	4.40	15.01	16.30	19.54	2.74	-3.10	5.19	1.26	13.33	13.14
Operating Margin	6.2	4.2	3.1	4.8	3.3	3.3	3.9	9.6	9.7	10.8	1.4	-1.7	2.6	0.8	6.8	6.9
Financing Income/(Expense) - Net	-2.51	-2.55	-2.62	-2.70	-2.60	-2.76	-2.74	-3.09	-2.91	-2.78	-2.55	-2.68	-5.36	-5.19	-6.53	-6.85
Profit before Taxes	1.36	0.94	1.10	2.06	0.22	1.78	2.36	12.33	14.09	17.27	1.74	0.09	0.61	-3.24	8.05	7.41
Income Taxes	0.30	0.21	0.23	0.41	0.04	0.43	0.65	4.82	3.20	3.56	0.60	0.27	0.47	-1.95	2.50	2.16
Profit after Tax	1.06	0.73	0.87	1.65	0.18	1.35	1.71	7.51	10.90	13.71	1.14	-0.18	0.14	-1.29	5.55	5.25
PAT Margin	1.7	0.9	0.9	1.6	0.2	1.3	1.5	4.8	6.5	7.6	0.6	-0.1	0.1	-0.8	2.8	2.8
EPS - Basic - ex Extraordinary Items	3.17	2.19	2.60	4.95	0.54	1.69	2.14	9.39	13.62	17.14	1.43	-0.23	0.17	-2.97	5.70	5.40
EPS - Diluted - ex Extraordinary Items	3.17	2.19	2.60	4.95	0.54	1.69	2.14	9.39	13.62	17.14	1.43	-0.23	0.17	-2.97	5.70	5.40
EBIT	3.76	3.32	3.01	5.11	3.25	3.56	4.40	15.01	16.30	19.54	2.74	-3.10	5.19	1.26	13.33	13.14
EBITDA	5.61	5.45	5.29	7.78	5.98	6.01	7.08	17.84	19.51	22.92	6.54	1.37	11.41	7.22	19.81	19.70
EBITDA Margin	9.2	6.8	5.5	7.3	6.0	5.6	6.3	11.4	11.7	12.6	3.3	0.8	5.8	4.5	10.1	10.3

Balance Sheet

Abridged

Understanding Balance Sheet

Everest Organics Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	C 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	C 2016 Mar 31	C 2017 Mar 31	C 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	30.82	32.63	40.93	41.90	44.65	49.24	58.17	66.85	79.14	89.25	117.88	132.48	149.98	147.90	167.43
Long-Term Investments	0.08	0.08	0.08	0.08	0.98	0.98	0.08	0.08	0.08	0.08	0.08	0.08	1.32	1.44	2.07
Property Plant & Equipment - Net	20.66	22.89	24.12	24.21	28.44	33.56	34.34	38.71	40.17	43.64	57.00	63.96	71.67	69.71	64.59
Total Non-Current Assets	21.21	23.73	24.52	24.77	31.22	36.80	36.12	40.43	41.16	46.13	60.12	69.37	76.74	76.58	72.37
Total Assets	52.03	56.35	65.46	66.67	75.87	86.04	94.29	107.28	120.29	135.38	178.00	201.85	226.72	224.48	239.80
Total Current Liabilities	43.61	47.65	51.19	49.58	56.05	63.37	67.42	71.10	74.01	77.36	112.56	137.58	160.10	139.92	152.20
Long Term Debt	5.13	4.68	10.11	11.29	4.77	4.77	6.45	4.66	4.61	6.99	13.34	12.28	14.64	9.20	7.28
Total Non-Current Liabilities	5.14	4.69	10.11	11.29	13.83	6.58	8.19	10.20	12.08	11.44	18.64	18.05	20.78	14.61	12.13
Total Liabilities	48.75	52.34	61.30	60.86	69.88	69.96	75.61	81.30	86.09	88.80	131.20	155.63	180.88	154.54	164.32
Total Shareholders' Equity	3.28	4.01	4.15	5.81	5.99	16.08	18.68	25.98	34.20	46.58	46.80	46.21	45.84	69.95	75.48
Total Equity	3.28	4.01	4.15	5.81	5.99	16.08	18.68	25.98	34.20	46.58	46.80	46.21	45.84	69.95	75.48
Total Liabilities & Equity	52.03	56.35	65.46	66.67	75.87	86.04	94.29	107.28	120.29	135.38	178.00	201.85	226.72	224.48	239.80

Cash Flow

Abridged

Understanding Cash Flow Statement

Everest Organics Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	R 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	3.07	2.92	2.97	4.39	2.98	4.19	5.32	10.46	14.41	16.95	4.82	4.29	5.42	2.22	14.02
Working Capital - Increase/(Decrease)	1.83	1.59	-6.49	-0.12	0.19	4.37	-6.17	-5.54	-4.57	-10.31	-4.84	-0.75	1.88	-8.06	-20.11
Net CF from Operating Activities	4.90	4.51	-3.52	4.27	3.17	8.56	-0.85	4.92	9.84	6.64	-0.02	3.54	7.30	-5.84	-6.09
Capital Expenditures - Net	4.69	4.35	3.27	2.76	6.96	7.58	3.46	7.20	7.19	6.85	17.15	13.53	13.09	5.43	1.96
Net CF from Investing Activities	-4.69	-4.35	-3.27	-2.76	-7.18	-7.64	-3.81	-5.46	-5.46	-10.73	-16.07	-15.78	-13.42	-5.43	-1.96
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	-	0.96	1.20	0.80	0.40	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	0.02	2.12	-	-	-	-	-	27.00	-
Debt - LT & ST - Issuance/(Retirement) - Total	-0.69	-0.21	6.83	-1.55	4.03	-8.87	4.42	-0.68	-3.38	4.95	15.88	12.27	6.12	-9.91	2.06
Net Cash Flow from Financing Activities	-0.69	-0.21	6.83	-1.55	4.02	-0.49	4.44	1.44	-4.34	3.75	15.08	11.87	6.12	17.09	2.06
Free Cash Flow to Equity	-0.48	-0.05	0.04	-0.04	0.23	-7.89	0.11	-2.96	-0.73	4.74	-1.29	2.27	0.33	-21.18	-5.99
Free Operating CF net dividend	0.21	0.16	-7.03	1.51	-3.80	0.98	-4.31	-2.28	1.68	-1.41	-17.98	-10.39	-5.79	-11.27	-9.32
Free Operating CF	0.21	0.16	-7.03	1.51	-3.80	0.98	-4.31	-2.28	2.65	-0.21	-17.18	-9.99	-5.79	-11.27	-9.32

Business Segment Analysis

FY End:

Mar 24

Everest Organics Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical ingredients (100.0%)₹ 13.09 Cr

Revenue / Sales

Pharmaceutical ingredients (100.0%)₹ 197.24 Cr

Assets

Pharmaceutical ingredients (100.0%)₹ 226.72 Cr

Operating Income

Pharmaceutical ingredients (100.0%)₹ 5.19 Cr

Regional Segment Analysis

FY End:

Mar 24

Everest Organics Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Domestic Segment (73.7%)₹ 145.36 CrExport Segment (26.3%)₹ 51.88 Cr

Historical Segment Analysis

Track how Everest Organics Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31
	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31
Pharmaceutical ingredients	7	7	7	17	14	13

Frequently Asked Questions

What is the revenue of Everest Organics Ltd.?

The latest trailing twelve month revenue of Everest Organics Ltd. is ₹ 190.77 Cr, reflecting a 1-year growth of 5.49% and a 3-year CAGR of 1.45%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Everest Organics Ltd.?

The latest trailing twelve month net profit (PAT) of Everest Organics Ltd. is ₹ 5.25 Cr, with a 3-year earnings CAGR of 18.35%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Everest Organics Ltd.?

The trailing twelve month EBITDA of Everest Organics Ltd. is approximately ₹ 12.96 Cr (based on an operating margin of 6.79%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Everest Organics Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Everest Organics Ltd. is 5.40. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Everest Organics Ltd.?

The debt-to-equity ratio of Everest Organics Ltd. stands at 0.66. The interest coverage ratio is 1.92x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Everest Organics Ltd.?

The estimated book value per share of Everest Organics Ltd. is 77.72 (derived from a P/B ratio of 3.86 and market price of ₹ 299.95), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Everest Organics Ltd.?

The trailing twelve month operating cash flow of Everest Organics Ltd. is ₹ -6.09 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Everest Organics Ltd. report consolidated or standalone financials?

Everest Organics Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.